Isosorbide mononitrate Vitabalans

Quick links

Choose a section

Quick links to important sections

Advertisements
Advertisements

Overview of Isosorbide mononitrate Vitabalans

This section defines the fundamental identity, composition, and general classification of the medicinal product, Isosorbide mononitrate Vitabalans.

Property Description
Active Ingredient Isosorbide Mononitrate
Form Oral Tablet
Pharmacological Class Vasodilator / Organic Nitrate
General Purpose Managing circulatory function and cardiac workload
Origin Synthetic Compound

Isosorbide Mononitrate: Definition, Composition, and Origin

Isosorbide mononitrate Vitabalans is a prescription-only medicinal product containing Isosorbide Mononitrate (INN) as its single, active component. This compound is a synthetic organic molecule classified as an organic nitrate. The preparation is manufactured as an oral tablet by the Finnish company Vitabalans Oy, establishing the product's origin and common formulation.

The use of the mononitrate form is deliberate: it is the primary active metabolite of the older drug, isosorbide dinitrate. This characteristic, which means the body does not need to perform an initial metabolic step for it to be active, contributes to a more predictable pharmacological profile.


What Pharmacological Class and Type is Isosorbide Mononitrate?

The active ingredient, Isosorbide Mononitrate, is firmly categorized within the pharmacological class of Vasodilators, officially listed as an Anti-anginal Agent. This classification confirms that the medicine's primary therapeutic action is causing the relaxation and widening of blood vessel walls.

This specific formulation is designed as a long-acting compound, which is a key distinguishing factor from fast-acting nitrates used for acute situations. This sustained action is crucial for its general role in providing continuous cardiovascular support, making it suitable for patients requiring consistent, scheduled management of their circulatory status.


What is the General Purpose of Isosorbide Mononitrate?

The general purpose of this medicine is to manage circulatory function by improving the balance between the heart's oxygen requirements and the blood supply available to it. By inducing widespread vascular relaxation, the medicine reduces the pressure and mechanical resistance the heart must work against during circulation. This decrease in cardiac workload enables the drug to fulfill its fundamental role of establishing a more efficient circulatory environment for ongoing cardiac management.

Advertisements

What side effects are possible with Isosorbide mononitrate Vitabalans?

Possible Side Effects and Safety Information

The safety profile of isosorbide mononitrate is largely defined by its vasodilating action. Side effects primarily involve the cardiovascular and nervous systems, with frequency classifications often following regulatory frameworks like those from the EMA.

Key Adverse Reactions by Frequency:

Frequency Examples (System-Organ Class)
Very Common (1/10) Headache (Nervous system disorders)
Common (1/100 to < 1/10) Dizziness, Hypotension (low blood pressure), Tachycardia (increased heart rate), Nausea, Fatigue (Vascular, Cardiac, Nervous, and Gastrointestinal disorders)
Uncommon (1/1,000 to < 1/100) Flushing, Vomiting, Diarrhea (Vascular and Gastrointestinal disorders)
Rare (1/10,000 to < 1/1,000) Fainting ( Syncope), Rash, Pruritus (itching) (Nervous system and Skin disorders)

Serious Safety Considerations

Isosorbide mononitrate is absolutely contraindicated with concomitant use of Phosphodiesterase type-5 inhibitors (e.g., sildenafil, tadalafil) or the soluble guanylate cyclase stimulator riociguat. Combining these medications can lead to severe, life-threatening hypotension or circulatory collapse. Severe hypotension may also occur, sometimes accompanied by paradoxical bradycardia (slow heart rate) or the aggravation of angina pectoris.

Safety Restrictions and Context-of-Use Notes

The drug is not for use in treating acute angina attacks. Caution is advised in patients with conditions such as severe anemia, hypertrophic cardiomyopathy, or pre-existing low blood pressure. Due to the potential for orthostatic hypotension (dizziness upon standing), patients should be monitored, and the drug must not be stopped suddenly. Safety in pregnancy, lactation, and the pediatric population has not been established and requires careful clinical assessment.

Advertisements

Overdose and Emergency Response

Official Documentation on Overdose and Emergency Action

An overdose of Isosorbide Mononitrate is a serious event that is documented in regulatory sources as potentially fatal. The clinical presentation is defined by the consequences of severe and persistent vasodilatation, primarily leading to a prompt fall in blood pressure.

Overdose Manifestations
Persistent throbbing headache and confusion
Vertigo, palpitations, and syncope (fainting)
Gastrointestinal effects including bloody diarrhea
Severe Outcomes
Severe hypotension and reduced cardiac output
Methemoglobinemia (impairing oxygen delivery)
Seizures (convulsions) and increased intracranial pressure

When to Seek Urgent Medical Help

Government regulatory documentation explicitly states that emergency medical attention must be sought immediately if an overdose is suspected or if severe manifestations occur.

Official Management Notes

The official documentation outlines specific supportive measures. Treatment is directed toward increasing central fluid volume to counteract venous pooling, which may involve intravenous fluid infusion. For the hematologic complication of methemoglobinemia, the specific treatment listed in prescribing information is the intravenous administration of Methylene Blue. Caution is advised, and specialized monitoring may be required when treating patients with co-existing renal failure or congestive heart failure due to the documented hazards of fluid administration.

Advertisements

Therapeutic Uses of Isosorbide mononitrate Vitabalans

Quick Facts

  • Primary Use: May help in the prevention of chest discomfort associated with a heart condition.
  • Therapeutic Domain: Coronary artery disease; long-term management of angina pectoris.
  • Action: Intended for regular, scheduled use to support the management strategy for this chronic condition.

Isosorbide mononitrate Vitabalans is part of a management strategy for individuals who experience angina pectoris, a form of chest discomfort resulting from coronary artery disease. The medication's purpose is to contribute to the prevention of anginal episodes, allowing for support in maintaining a degree of physical activity and quality of life.

This medication is not designed to address an acute or ongoing episode of chest discomfort. Its role involves regular administration as a prophylactic measure to support the circulatory system's operation and help reduce the likelihood of future occurrences of angina. The goal of treatment is to help manage the symptoms of chronic coronary artery disease.

Advertisements

Eligibility and Restrictions for Use

Eligibility and Contraindications for Isosorbide Mononitrate

Isosorbide mononitrate is approved for use in adults for the prophylaxis of angina pectoris. However, regulatory documents establish specific populations who must not use the medicine (absolute contraindications) and others where use is restricted or requires caution.


Absolute Contraindications

The medicine is contraindicated and must not be used by patients with:

  • Known allergy to nitrates (including isosorbide dinitrate).
  • Concomitant use of Phosphodiesterase Type 5 (PDE-5) Inhibitors (e.g., sildenafil, tadalafil) or the soluble guanylate cyclase (sGC) stimulator riociguat.
  • Severe hypotension (very low blood pressure) or acute circulatory failure (shock).
  • Hypertrophic obstructive cardiomyopathy (HOCM), constrictive pericarditis, or cardiac tamponade.
  • Marked anaemia (severe anaemia).

Population Restrictions

Population Regulatory Status
Paediatric Population Use Not Established. Safety and efficacy are not established in children or adolescents.
Pregnancy/Lactation Restricted Use. Safety is not established; use only if potential benefit justifies the risk. Excretion into human milk is unknown.
Severe Hepatic/Renal Impairment Caution Advised. Should be used with caution, and monitoring is recommended.
Older Adults Use is Acceptable. No routine dosage adjustment is needed, but caution is advised with pre-existing organ insufficiency.
Advertisements

What should I know about interactions with other medicines?

Interactions with other medicines and products

Isosorbide mononitrate can interact with several medicinal products and substances, primarily due to additive effects on blood pressure. These interactions are categorized based on their clinical significance and regulatory status.

1. Contraindicated Combinations

Co-administration of isosorbide mononitrate with the following substances is strictly contraindicated due to the risk of severe, life-threatening hypotension and syncope:

  • Phosphodiesterase type 5 (PDE-5) Inhibitors (e.g., sildenafil, tadalafil, vardenafil, avanafil).
  • Soluble Guanylate Cyclase (sGC) Stimulators (e.g., riociguat).

2. Pharmacodynamic Interactions

Concomitant use with other agents that lower blood pressure may result in additive hypotensive effects or orthostatic hypotension. These include:

  • Other Vasodilators
  • Antihypertensive Agents (e.g., Calcium Channel Blockers, Beta-blockers)

3. Food and Lifestyle Substance Interactions

Consumption of alcohol is known to potentiate the blood pressure-lowering effects of isosorbide mononitrate, which may lead to light-headedness or dizziness. No specific interactions with food or common herbal products are documented as clinically significant in the official labeling.

4. Timing and Tolerance

Due to the development of pharmacodynamic tolerance, the drug's prescribed regimen includes a nitrate-free interval to maintain its long-term efficacy. The clearance of isosorbide mononitrate occurs primarily by denitration and glucuronidation, yielding inactive metabolites.

Advertisements

Mechanism of Action

Activating the Nitric Oxide ( NO) Pathway

This organic nitrate acts as a dedicated Nitric Oxide ( NO) Donor, meaning it releases NO through bioactivation in the body. The liberated NO then directly targets and stimulates the enzyme soluble Guanylyl Cyclase ( sGC) inside vascular smooth muscle cells. This interaction initiates the cellular cascade by increasing levels of the second messenger cyclic Guanosine Monophosphate ( cGMP), which mediates the subsequent physiological responses.


Vasodilation via cGMP and Reduced Ca^2+

The surge in cGMP leads to a sequence of events that results in the functional reduction of intracellular calcium ( Ca^2+). The reduction of calcium, the molecular trigger for muscle contraction, causes the smooth muscle cells lining the blood vessel walls to relax, a physiological process known as vasodilation. This mechanism produces vasodilation, which directly changes the dimensions of the circulatory system.


Systemic Reduction of Cardiac Workload (Preload/Afterload)

The resulting widespread vasodilation preferentially affects the large veins, leading to blood pooling peripherally and significantly decreasing the volume of blood returning to the heart (cardiac preload). Simultaneously, a lesser degree of arteriolar dilation reduces the resistance the heart pumps against (cardiac afterload). The combined reduction in both preload and afterload dictates the overall physiological consequence: a lowering of the heart muscle's total workload.

Advertisements

Dosage and Administration Information

How to Use Isosorbide Mononitrate: Administration Guidelines

Isosorbide mononitrate is administered via the oral route in the form of tablets, which are intended for long-term, chronic prophylactic use. The primary principle governing its use is the adherence to an asymmetric dosing schedule to ensure a daily dose-free interval, which is essential for maintaining the drug’s effectiveness.

Dosing and Frequency

Formulation Type Starting Dose Maintenance Schedule Special Instruction
Immediate-Release (IR) 10 mg or 20 mg 20 mg to 120 mg total daily dose, divided and taken two or three times daily. Doses must be spaced apart (e.g., 7 hours) to create a nitrate-free period.
Extended-Release (ER) 30 mg or 60 mg Taken once daily, typically in the morning. Maximum dose is generally 120 mg daily. Must be swallowed whole; do not crush, chew, or split.

Administration Specifics

Tablets may be taken with or without food and should be swallowed whole with fluid.

When discontinuing the medicine after long-term use, the instruction is to gradually taper the dosage and frequency; treatment should not be stopped suddenly. Dose titration (increase) should also be undertaken gradually over several days to find the appropriate long-term regimen.

Population-Specific Use

Safety and efficacy have not been established for use in children. For older adults and patients with marked hepatic or renal insufficiency, dosage reduction should be considered.

Advertisements

Recent Clinical Evidence

Research Evidence / Overview of Studies for Isosorbide Mononitrate Vitabalans

Evidence for Use in Stable Angina Pectoris

Research exploring stable angina pectoris primarily consists of Randomized Controlled Trials (RCTs), utilizing double-blind and crossover designs. These studies were applied in research contexts involving fluctuating or unstable symptoms in adults diagnosed with chronic, effort-induced angina. Research examined outcomes related to physical discomfort and performance, primarily monitoring measurements of activity level through standardized tests, such as how long a patient could exercise before symptoms appeared. Researchers also observed how patients reported their experiences, tracking the weekly frequency of anginal episodes and the corresponding use of fast-acting rescue medications.

In these short-term research scenarios, findings describe patterns observed in the studies related to exercise duration and the time taken until symptoms became more noticeable during testing. Studies monitored reported outcomes describing episodic or acute changes in symptom activity and the need for rescue medication. Reported patterns were observed across the available short-term trials regarding these specific endpoints.

Research in Other Clinical Situations

Studies have explored the use of Isosorbide mononitrate for other complex conditions, including a specific type of heart failure known as Heart Failure with Preserved Ejection Fraction (HFpEF). Research exploring short-term changes in this patient population included multicenter, double-blind RCTs. These studies primarily focused on outcomes reflecting daily functioning or activity level. In these trials, findings describe patterns related to activity that did not suggest measured improvement in the primary objective daily functioning endpoint. Furthermore, some studies reported how symptoms evolved in the observed populations, describing a potential decrease in activity that was associated with increasing dosages compared to the placebo group.

What Remains Unestablished by Research

Research is ongoing, and several key areas remain uncertain. The existing studies provide context but not individual predictions, and the evidence highlights what is known — and what is still uncertain. The primary limitations include that follow-up durations were limited across many trials, particularly when monitoring life-altering clinical events, such as heart attack or stroke. Data for certain groups remain insufficient, as research has primarily included adults, and the study results reflect the specific conditions and populations under which they were conducted.

Key Studies & References

  1. Isosorbide Mononitrate Extended-Release Tablets, USP Rx only - DailyMed (FDA-Approved Labeling)
  2. Meta-analysis: isosorbide-mononitrate alone or with either beta-blockers or endoscopic therapy for the management of oesophageal varices
Advertisements

Frequently Asked Questions (FAQ)

Common questions about Isosorbide mononitrate Vitabalans (FAQ)

Q: How does Isosorbide mononitrate compare to nitroglycerin (glyceryl trinitrate)?

According to official information, Isosorbide mononitrate is categorized as a long-acting nitrate intended for prevention of chest pain, with a gradual onset of action. It is specifically not indicated for the treatment of a sudden, acute episode of chest pain, which is the established role of fast-acting nitrates such as nitroglycerin.

Q: Why are headaches a very common side effect when first starting this medication?

Headaches are commonly reported when initiating this treatment. They are often regarded as a sign of the drug's intended action of widening blood vessels (vasodilation) that the medicine is designed to produce.

Q: What is meant by the term 'tolerance' in the context of nitrate medications?

The term 'tolerance' refers to a state where the drug's effectiveness may be reduced when it is continuously present in the body at high concentrations. Regulatory documents indicate that this is why the prescribed regimen includes a daily dose-free interval to help maintain the long-term effectiveness of the medication.

Q: Does Isosorbide mononitrate Vitabalans have any documented effects on existing kidney function?

Official product information advises that the medicine is primarily eliminated as inactive metabolites by the kidney. Therefore, a reduced dosage may be indicated for patients who have marked renal insufficiency (severe kidney impairment).

Q: Is Isosorbide mononitrate chemically similar to Isosorbide dinitrate?

Yes, Isosorbide mononitrate is closely related to Isosorbide dinitrate. It is the major biologically active metabolite of the older drug, meaning the body processes the dinitrate into the mononitrate, which is the compound that performs the therapeutic action.

Q: Is it possible for a person to have an allergic reaction to the inactive ingredients in the tablet?

Official patient information advises that individuals are advised to inform their healthcare providers about any known allergies, not only to the active drug itself but also to any of the inactive ingredients (excipients) used in the tablets.

Q: What is the meaning of the extended-release (ER) or sustained-release (SR) designation sometimes used with this drug class?

The extended-release (ER) or sustained-release (SR) designation indicates that the tablet is formulated to release the active medicine slowly and consistently into the body over a longer period. This allows the medication to be taken once daily while still providing continuous support for prevention.

Q: Are there official warnings about combining this drug with herbal supplements?

Regulatory information suggests that there is often not enough clinical information to confirm that common herbal remedies or supplements are safe to use alongside this medication. It is generally recommended to inform your healthcare team about any such products you take.

Q: Are the headaches associated with this drug generally temporary?

Official patient information indicates that the headaches associated with starting this medicine usually go away after the first few days of treatment as the body adjusts. Simple pain relievers may be considered for temporary relief, according to official patient information.

Q: Are there known interactions between Isosorbide mononitrate Vitabalans and common over-the-counter pain relievers?

Regulatory guidance indicates that paracetamol is generally safe to take with this medication. However, certain common non-steroidal anti-inflammatory drugs (NSAIDs, such as ibuprofen) should generally be avoided for regular use unless supervised by a physician.

Q: What types of cold and flu medications are generally advised against when on nitrate therapy?

Official sources advise caution with cold and flu medications. Certain ingredients, such as those that might also lower blood pressure or cause sedation, can have additive effects, potentially leading to increased dizziness or lightheadedness when combined with this nitrate medicine.

Q: How long does it typically take for the body to adjust to the medication after starting treatment?

When starting treatment or undergoing a dose increase, certain effects like dizziness or lightheadedness typically resolve or lessen after the first few days as the body adjusts to the presence of the medication.

Q: Are there specific official warnings for people with pre-existing thyroid conditions?

Yes, official patient information states that this medicine may not be suitable for people who have a pre-existing diagnosis of an underactive thyroid (hypothyroidism). Clinical guidance is always important to determine appropriateness of use.

Q: What are common physical signs that may indicate low blood pressure related to this drug?

Common physical signs that may indicate low blood pressure (hypotension) due to this medication include feeling dizzy, lightheaded, or faint. Other signs can include nausea or a sudden, noticeable change in heart rate or pulse.

Q: What does regulatory information advise about driving or operating heavy machinery while taking this?

Official product labeling advises patients to be cautious when driving or operating heavy machinery until they are certain how the medicine affects them. This caution is due to the potential for side effects such as tiredness, dizziness, or light-headedness.

Q: Is this drug considered appropriate for people who have recently experienced a major cardiovascular event?

Regulatory documents indicate that the benefits of this medicine for patients with conditions such as acute myocardial infarction (heart attack) or congestive cardiac failure have not been established by research. Use in such settings necessitates careful clinical supervision.

Q: Why is this specific drug only available through a prescription?

Isosorbide mononitrate is classified as a prescription-only medication (Rx-only) because it is used to manage a chronic and serious medical condition, stable angina pectoris. Its safe and effective use is determined to require professional medical supervision for diagnosis and dose adjustment.

Q: How is the effect of this medication typically monitored by healthcare professionals during treatment?

Monitoring the effect of this medicine is primarily clinical, meaning it focuses on checking for symptom recurrence (angina), noting reflex changes in heart rate, and regularly monitoring blood pressure during dose adjustments. Routine laboratory testing is generally not required.

Q: Does taking this medication have a known impact on blood sugar levels?

Studies reviewed by regulatory bodies have generally found no significant effect of this medicine on blood sugar levels or on the body's sensitivity to insulin in individuals with coronary artery disease.

Q: Does Isosorbide mononitrate Vitabalans have an officially documented risk of physical withdrawal symptoms?

Official labeling advises gradual tapering of the dose when stopping the medicine. While there have been reports of physical dependence in industrial workers exposed to large amounts of nitrates, studies in clinical patient settings regarding withdrawal upon abrupt cessation have shown mixed results.

Q: Is this medication generally considered a first-line or second-line treatment for its primary indication?

Clinical practice guidelines often position long-acting nitrates like this as a second-line treatment option for its primary indication. This means it is typically considered when first-line therapies (such as beta-blockers) are poorly tolerated, contraindicated, or are not fully controlling symptoms.

Q: Is it safe to undergo routine dental procedures while regularly taking this medication?

Regulatory patient information from authoritative sources advises that if you are planning to undergo any surgical procedure, including routine dental surgery, you are advised to inform the doctor or dentist that you are taking this medication.

Q: What is the known relationship between this drug and conditions that increase eye pressure (glaucoma)?

Official precautions advise caution for use in patients with angle-closure glaucoma. Sudden, severe eye pain, blurred vision, or headache could be potential signs of acute angle-closure glaucoma, which is a serious condition that warrants immediate clinical assessment.

Q: What does 'mononitrate' signify about the chemical structure of the drug?

The term 'mononitrate' is a chemical description referring to the presence of a single nitrate group ( NO3) within the molecule of the active ingredient, which dictates its chemical structure and pharmacological properties.

Advertisements

How should Isosorbide mononitrate Vitabalans be stored and disposed of?

How to Store and Dispose of Isosorbide Mononitrate Vitabalans

Isosorbide mononitrate tablets must be stored according to specific regulatory conditions to maintain their integrity.

Storage Requirements

Storage Condition Requirement
Temperature Store at a Controlled Room Temperature (CRT), typically between 15 C to 30 C (59 F to 86 F). Do not allow the product to freeze.
Protection Keep the tablets in a tightly closed container, protected from heat, excessive moisture, and direct light. Store in a dry place.
Child Safety The medicine must be kept strictly out of the sight and reach of children.
Stability Do not use the medicine after the expiration date printed on the packaging.

Disposal Instructions

Outdated or unused medicine must not be kept. Patients should consult a healthcare professional or pharmacist for instructions on how to properly dispose of the medicine. Disposal must be in accordance with applicable local laws and regulations, avoiding discharge into sewer systems or household waste, as mandated by regulatory documents for pharmaceutical products.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Isosorbide mononitrate Vitabalans found in:

A-Z Index: